KOD Kodiak Sciences Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1468748 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-13.5%
TTM EPS YoY1.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-1,360.9%
ROA-115.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets94.0%
Debt / equity0.00x
Current ratio1.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.69x
Accruals ratio-36.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $58.30M | $56.08M | $48.55M | $45.49M | $50.48M | $42.76M | $43.64M | $31.77M |
| SG&A expense | $8.79M | $10.76M | $11.23M | $11.96M | $11.88M | $12.75M | $15.43M | $14.41M |
| Operating income | -$67.10M | -$66.84M | -$59.78M | -$57.45M | -$62.35M | -$55.51M | -$59.07M | -$46.18M |
| Interest expense | — | — | — | — | — | — | — | $0 |
| Net income | -$66.22M | -$65.64M | -$58.16M | -$56.74M | -$61.46M | -$54.31M | -$57.46M | -$44.10M |
| EBITDA | -$63.01M | -$62.73M | -$55.67M | -$52.91M | -$57.77M | -$50.92M | -$54.47M | -$41.55M |
| EPS (basic) | -1.05 | -1.05 | -0.94 | — | -1.16 | -1.03 | -1.09 | — |
| EPS (diluted) | -1.05 | -1.05 | -0.94 | — | -1.16 | -1.03 | -1.09 | — |
| Weighted avg. shares (diluted) | 62.96M | 62.63M | 61.86M | — | 52.86M | 52.78M | 52.75M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $88.68M | $125.90M | $169.53M | $209.86M | $72.04M | $104.17M | $138.85M | $168.07M |
| Current assets | $92.89M | $131.36M | $175.26M | $214.82M | $75.73M | $107.92M | $142.69M | $171.94M |
| PP&E, net | $75.64M | $78.31M | $81.51M | $85.26M | $88.91M | $93.43M | $97.90M | $102.22M |
| Total assets | $209.41M | $256.81M | $306.01M | $351.53M | $218.07M | $256.73M | $297.91M | $335.58M |
| Current liabilities | $54.74M | $52.77M | $49.57M | $45.53M | $42.43M | $31.01M | $30.88M | $25.57M |
| Total liabilities | $196.84M | $195.72M | $193.91M | $194.15M | $194.38M | $186.44M | $189.07M | $185.29M |
| Shareholders' equity | $12.57M | $61.10M | $112.10M | $157.38M | $23.69M | $70.29M | $108.84M | $150.29M |
| Shares outstanding | 64.31M | 62.83M | 62.16M | 61.76M | 53.00M | 52.82M | 52.75M | 52.73M |
| Cash flow statement | ||||||||
| Operating cash flow | -$43.87M | -$46.24M | -$40.01M | -$39.38M | -$32.88M | -$34.67M | -$29.08M | -$30.07M |
| Capital expenditure | $1.98M | $352,000 | $942,000 | $43,000 | $60,000 | $133,000 | $270,000 | $124,000 |
| Free cash flow | -$45.84M | -$46.59M | -$40.95M | -$39.42M | -$32.94M | -$34.81M | -$29.35M | -$30.19M |
| Investing cash flow | -$1.98M | -$352,000 | -$942,000 | -$43,000 | -$60,000 | -$133,000 | -$270,000 | -$124,000 |
| Financing cash flow | $6.38M | $2.96M | $619,000 | $177.25M | $813,000 | $120,000 | $124,000 | $404,000 |
| Depreciation & amortization | $4.09M | $4.11M | $4.11M | $4.54M | $4.59M | $4.59M | $4.60M | $4.63M |
| Stock-based compensation | $12.80M | $11.61M | $12.15M | $13.29M | $14.05M | $15.64M | $15.89M | $8.62M |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.